Na Cocer Peptides 
15 mau lā aku nei
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.
Nānā o BPC-157
ʻO BPC-157 kahi pentapeptide gastrointestinal paʻa i ʻike mua ʻia no kāna mau waiwai anti-ulcer. Noho paʻa ia i loko o ka wai ʻōpū o ke kanaka no nā hola he 24, e hiki ai iā ia ke hoʻomau i kona hopena i loko o ka ʻōpū o ka ʻōpū a kau i ke kumu no ka hoʻoponopono ʻana i ka ʻōpū a me ka pōʻino hui. ʻO kona ʻano kemika
ʻo GEPPPGKPADDAGLV, me ke kaumaha molekala o 1419. Hiki i kēia ʻano molekala ke launa pū me nā biomolecules like ʻole i loko o ke kino, a laila e hoʻokō i nā hana physiological koʻikoʻi.
Kiʻi 1 BPC-157 hoʻoikaika i ka hoʻonui ʻana a me ka puʻupuʻu cell cycle o HUVEC.
Nā hopena hoʻoponopono o BPC-157 i ka pōʻino o ka ʻōpū
Ka pale ʻana i nā maʻi ʻōpū a me ka mālama ʻana i ka pono o ka ʻōpū
He kuleana koʻikoʻi ka BPC-157 i ka pale ʻana i nā ʻōpū o ka ʻōpū, pale pono i nā hopena ʻino o nā lāʻau like ʻole ma ka ʻōpū. ʻO nā mea e like me ka waiʻona a me nā lāʻau anti-inflammatory nonsteroidal (NSAIDs) e hoʻopōʻino pinepine i nā ʻōpū o ka ʻōpū a hoʻopau i ka pono o ka ʻōpū. Hiki i ka BPC-157 ke pale i nā ʻōpū o ka ʻōpū mai ka pōʻino pololei e kēia mau mea ʻino ma o ke ʻano o nā mīkini physiological paʻakikī. Ke ʻike ʻia i ka hoʻoulu ʻana i ka waiʻona, hoʻoponopono ʻo BPC-157 i nā ala metabolic i loko o nā ʻōpū o ka ʻōpū, hoʻonui i ka ʻōnaehana pale antioxidant o nā cell, a hoʻemi i ka pōʻino oxidative i hoʻokumu ʻia e nā metabolites waiʻona. No ka NSAID-induced gastric mucosal poino, BPC-157 e hoʻoikaika i nā ala hōʻailona intracellular e kaohi i ka hoʻokuʻu ʻana o nā mea hoʻopuʻi inflammatory, a laila e hoʻēmi i nā hopena luku o nā pane inflammatory ma ka mucosa ʻōpū. Kōkua kēia i ka mālama pono ʻana i ka ʻōpū o ka ʻōpū a hōʻoia i nā hana physiological maʻamau o ka ʻōpū.
Hōʻike 2 BPC-157 i hoʻonui i ka reepithelialization ʻeha a me ka ʻike collagen o ka ʻiʻo granulation.
Hoʻopaʻa i ka paʻa o ka ʻōpū
ʻO ka piʻi ʻana o ka ʻōpū i loko o ka ʻōpū he mea koʻikoʻi i ka ulu ʻana o nā maʻi ʻōpū he nui. ʻO nā mea hoʻonāukiuki o ka ʻōpū, e like me ke koʻikoʻi o ke kino a i ʻole ka noʻonoʻo, ka hoʻohana ʻana i ka NSAID, ka hoʻoulu ʻana i ka bile acid surfactant stimulation, a me ka inu ʻana i ka waiʻona, hiki i nā mea āpau ke alakaʻi i ka hoʻonui ʻana i ka epithelial permeability, e hoʻoulu ai i ka maʻi leaky gut. Hiki i ka BPC-157 ke hoʻopaʻa i ka permeability o ka ʻōpū ma o ka hoʻoponopono ʻana i nā protein junction paʻa ma waena o nā cell epithelial intestinal, ma laila e hoʻonui ai i ka ikaika pili intercellular. Wahi a ka ʻikepili, i nā ʻano holoholona i hōʻike ʻia i nā kumu koʻikoʻi i ʻōlelo ʻia ma mua, ua hoʻonui ʻia ka hoʻohana ʻana o BPC-157 i ka hoʻonui ʻana i ka hōʻike ʻana o nā protein junction paʻa ma waena o nā pūnaewele epithelial intestinal, me nā hale i hoʻonohonoho paʻa ʻia, a laila e hōʻemi ana i ka permeability intestinal i nā mole nui. Hoʻopau maikaʻi kēia i nā hōʻailona o ka leaky gut syndrome, hoʻemi i ka pilikia o nā mea ʻino e komo i ke kahe koko mai ka ʻōpū, a mālama i ka paʻa o ka microenvironment intestinal.
Hoʻoikaika i ka hoʻōla ʻana i ka ʻeha o ka ʻōpū
Inā ma ke kaʻina hana ho'ōla o ka ʻeha ma ka ʻōpū o ka ʻōpū a i ʻole nā fistulas waho (e like me nā fistulas ʻili esophageal, nā fistulas ʻili ʻōpū, nā fistulas ʻili duodenal, a me nā fistulas ʻili colonic) a me nā fistulas kūloko (e like me nā fistula colonic bladder a me nā fistula vaginal rectal) o ka ʻōpū o ka ʻōpū, BPC-157 hōʻike i nā hopena hoʻolaha nui. Hoʻoikaika ka BPC-157 i ka hoʻonui a me ka neʻe ʻana o nā fibroblasts, hoʻolalelale i ka synthesis collagen a me ka waiho ʻana, a laila hāʻawi i ke kākoʻo matrix e pono ai no ka ho'ōla ʻana. Hoʻoponopono pū ia i nā pane inflammatory kūloko, huki i nā cell immune i ka wahi ʻeha e hoʻomaʻemaʻe i nā pathogens a me nā ʻiʻo necrotic, a hoʻoikaika i ka angiogenesis, e hōʻoia i ka lako meaʻai a me ka oxygen kūpono no ka ho'ōla ʻana. Ma ke kaʻina anastomosis gastrointestinal, ke kū nei ka pūnaewele anastomotic i nā pilikia ho'ōla ma muli o nā kumu e like me NSAIDs, cystamine, a colectomy paha, hiki i ka BPC-157 ke pāʻani i ka hana maikaʻi i ka hoʻoikaika ʻana i ka ho'ōla anastomotic a me ka hōʻemi ʻana i ka pilikia o nā pilikia e like me ka anastomotic fistula.
Nā hopena i ka maʻi pancreatic a me ka gastrointestinal
Ma kahi ʻano ʻiole o ka maʻi maʻi pancreatitis i hoʻoulu ʻia e ka bile duct ligation, ua hōʻike ʻo BPC-157 i nā hopena pale i ka pancreas inā hoʻohana ʻia ma ke ʻano he mea pale a lapaʻau paha. ʻO ka mālama prophylactic o BPC-157 i hoʻemi nui i ka paʻakikī o ka pancreatitis, hoʻemi i ka necrosis pancreatic, edema, a me ka neutrophil infiltration, ʻoiai e hoʻonui ana i nā helu monocyte. I ka mālama ʻana i ka maʻi pancreatitis koʻikoʻi i loaʻa mua, ua ʻike pū ʻia nā hopena maikaʻi nui, me ka mālama ʻana i nā pae serum amylase. He hopena maikaʻi hoʻi ka BPC-157 i nā lesions gastric a me duodenal concurrent, e kōkua ana e mālama i ka pono o ka mucosa gastrointestinal a hoʻemi i ka pōʻino inflammatory i ka ʻōpū a me ka duodenum.
ʻO nā hopena hoʻoponopono o BPC-157 i ka pōʻino hui
Hoʻonui i ka osteoarthritis joint temporomandibular
I loko o ka iole kükohu o temporomandibular hui osteoarthritis, hui poino i induced surgically, e like me unilateral condylar articular ili poino, lateral collateral ligament o ka articular disc, a me hope disc attachment pae incisions, e simulate ke kaʻina pathological o osteoarthritis. Ma hope o ka hana ʻana, ua lawelawe ʻia ʻo BPC-157 ma o ka hoʻokele intraperitoneal. Ma ka loiloi 6-mahina hope, ua hōʻike ka hui mālama BPC-157 i ka piʻi nui o ka mānoanoa cartilage hui āpau i hoʻohālikelike ʻia i ka pūʻulu mana. ʻO ka mea kikoʻī, ua hōʻike ʻia kēia ma ke ʻano he mānoanoa nui ma ka ʻāpana cartilage a me ka ʻāpana hui, hoʻemi ʻia ka hoʻohui ʻana o ka cartilage cell, nalowale o nā māwae cartilage vertical, a me ka mālama ʻana i ka waiho ʻana o ka cartilage maʻamau. Hōʻike kēia e hiki i ka BPC-157 ke hoʻohaʻahaʻa pono i nā loli pathological o ka osteoarthritis joint temporomandibular a hoʻoikaika i ka hoʻoponopono a me ka hana hou ʻana o ka cartilage articular. Hiki ke pili ka hana o ka hana i ka pilina o BPC-157 me nā mole e like me ka collagen a me nā proteoglycans e pili ana i ka hoʻomohala ʻana o ka cartilage articular. Wahi a ka noiʻi, nui nā kumu o ka BPC-157 i hoʻopaʻa ʻia i ka collagen α-1 (I), collagen α-1 (IX), aggrecan, fibronectin precursor, chondroitin sulfate proteoglycan NG2 precursor, a me chondroitin oligosaccharide precursor, he mea koʻikoʻi no ka mālama ʻana i ka cartilage a me ka hana. Hiki i ka BPC-157 ke hoʻoikaika i ka hoʻoponopono ʻana a me ke kūkulu hou ʻana o ka cartilage hui ma o ka hoʻoponopono ʻana i ka ʻōlelo a i ʻole ka hana o kēia mau mole.
Hoʻonui ka Figure 3 BPC-157 i ka hōʻike ʻana o VEGF-a i nā ʻili ʻili ʻeha.
Hoʻoponopono i nā ʻeha hui kuli
ʻO ka ʻeha hui kuli he hōʻailona lapaʻau maʻamau i hoʻokumu ʻia e nā kumu like ʻole, e like me ka osteoarthritis, nā waimaka meniscus, nā maʻi tendon, nā waimaka ligament, a i ʻole nā ʻōpala. Ua ʻike ʻia kahi noiʻi retrospective he 17 mau maʻi me ka ʻeha hui kuli, me 16 mau maʻi e hahai ana. Ma waena o kēia mau maʻi, ua loaʻa iā 12 nā injections intra-articular o BPC-157 wale nō, me 11 (91.6%) i ʻike i ka hoʻomaikaʻi nui ʻana i ka ʻeha o ke kuli; ʻo nā maʻi 4 i koe i loaʻa i nā injections hui o BPC-157 a me thymosin-β4, me ka 75% o kēia mau maʻi e loaʻa ana i ka hōʻeha ʻeha nui. Ma keʻano holoʻokoʻa, 87.5% o nā maʻi i loaʻa ka hōʻoluʻolu o ka ʻeha o ke kuli ma hope o ka hoʻohana ʻana i ka BPC-157 a i ʻole ka hui pū ʻana me thymosin-β4. Hōʻike kēia i ka maikaʻi o ka BPC-157 i ka hoʻēmi ʻana i nā ʻano ʻeha o ke kuli. Hōʻike hou ka nānā ʻana he hiki i ka BPC-157 ke hoʻoponopono i nā waimaka a hoʻoikaika i ka hanauna cartilage, ʻo ia paha ke kumu koʻikoʻi no ka hana ʻana i ka ʻeha o ke kuli. I ka wā o ka hoʻoponopono ʻana i nā ʻeha hui, hiki i ka BPC-157 ke hoʻoikaika i ka hoʻonui a me ka hoʻokaʻawale ʻana o nā chondrocytes, hoʻonui i ka synthesis o ka cartilage matrix, a laila hoʻoponopono i ka ʻiʻo cartilage i hōʻino ʻia. Hoʻohui ʻia, hiki ke hana i kahi hopena reparative i nā ligaments i hōʻino ʻia, nā tendons, a me nā ʻiʻo ʻē aʻe, e hoʻomaikaʻi ai i ka paʻa ʻana a me ka hoʻohaʻahaʻa ʻana i ka ʻeha i hoʻokumu ʻia e ka hui pū ʻana.
Hoʻoponopono i nā ʻeha o ka hui ʻana o ka tendon-muscle
Ma hope o ka hoʻokaʻawale ʻia ʻana o ke tendon o ka ʻiʻo quadriceps kūpono i nā ʻiole, ua hōʻike ʻia ka mālama ʻana me BPC-157 i nā hopena therapeutic koʻikoʻi. Mai kahi loiloi macroscopic, ua hōʻike ka pūʻulu mana i kahi kīnā nui ma waena o ka tendon quadriceps a me ka ʻiʻo i hoʻomau i ka holomua, ka hopena i ka hoʻōla ʻole. ʻO ka ʻokoʻa, ʻo nā ʻiole i mālama ʻia me ka BPC-157 ua hōʻike i ka hoʻōla mau ʻana, me ka liʻiliʻi o ka hemahema mai ka hoʻomaka ʻana, e alakaʻi ana i ka hoʻihoʻi kumu o ka pilina tendon-muscle. Ua hōʻike ʻia ka hōʻike microscopic e hōʻike ana ka pūʻulu mana i ka edema tendon, infiltration lymphocytic liʻiliʻi, a me ka hoʻokumu ʻana o ka ʻiʻo granulation ma ka lua o ka pule ma hope o ka ʻoki ʻana, akā ʻo ka hui mālama BPC-157 i hōʻike wale i ka infiltration lymphocytic haʻahaʻa, ʻaʻohe hoʻokumu ʻana o ka granulation, a me ka hoʻihoʻi maikaʻi ʻana i ke ʻano pili o ka tendon-muscle. Hōʻike ka loiloi biomechanical i ka maikaʻi o ka hoʻihoʻi ʻana i ka ikaika o ka ʻiʻo ma ka hui hoʻomalu, aʻo ka hui mālama BPC-157 i loaʻa i ka hoʻōla piha. Hōʻike kēia i ka BPC-157 ʻaʻole wale nā hopena therapeutic ma nā ʻiʻo ʻeha a me nā tendons akā hōʻike pū kekahi i nā hopena reparative a me nā hopena therapeutic i ka pōʻino i ka hui tendon-muscle, kōkua i ka hoʻihoʻi ʻana i ka pilina maʻamau a me ka hana ma waena o nā ʻiʻo a me nā tendons a me ka hōʻoia ʻana i ka neʻe ʻana maʻamau.
Hiki a me nā manaʻo o BPC-157 i nā noi lapaʻau
Lapaʻau ʻana i nā maʻi ʻōpū
Hāʻawi ʻia i nā hopena pale o ka BPC-157 ma nā ʻōpū o ka ʻōpū, ka hoʻopaʻa ʻana i ka permeability o ka ʻōpū, ka hoʻoikaika ʻana i ka hoʻōla ʻana i ka ʻeha o ka ʻōpū, a me ka hopena maikaʻi i ka pancreatic a me ka gastric-duodenal lesions, paʻa ia i ka mana nui i ka mālama ʻana i nā maʻi ʻeha like ʻole. I ka mālama ʻana i nā ʻōpū ʻōpū a me nā ʻeha duodenal, hiki i ka BPC-157 ke hoʻolalelale i ka hoʻōla ʻana o ka maʻi ʻeha a hoʻemi i ka pilikia o ka hoʻi hou ʻana. No nā maʻi ʻeha o ka ʻōpū e like me ka ulcerative colitis, hiki i ka BPC-157 ke hoʻomaikaʻi i ka hana pale mucosal intestinal ma ka hoʻoponopono ʻana i nā pane o ka ʻōpū a me ka inflammatory, hoʻēmi i nā hōʻailona, a hoʻoikaika i ke kala ʻana i ka maʻi. Ma hope o ka ʻoki ʻana i ka ʻōpū, hiki i ka hoʻohana ʻana i ka BPC-157 ke kōkua i ka hoʻōla ʻana i ka anastomotic, hoʻemi i ka ulu ʻana o nā pilikia, a me ka hoʻolalelale i ke kaʻina hana hoʻōla o ka mea maʻi.
Lapaʻau ʻana i nā maʻi hui
Ma ke kahua o nā maʻi hui, nā hopena reparative o BPC-157 i ka osteoarthritis joint temporomandibular a me nā ʻeha kuli e hāʻawi i nā ʻike hou i kāna noi kūpono i ka mālama ʻana i ka osteoarthritis a me nā ʻeha haʻuki. No nā poʻe maʻi osteoarthritis, hiki i ka BPC-157 ke lilo i lāʻau lapaʻau hiki ke hoʻololi i ka maʻi, ʻaʻole wale e hoʻohaʻahaʻa i nā hōʻailona ʻeha akā e hoʻolōʻihi i ka degeneration cartilage, hoʻoikaika i ka hoʻoponopono cartilage, a me ka hoʻomaikaʻi ʻana i ka hana hui. I ka mālama ʻana i nā ʻeha haʻuki, e like me ka ʻeha a me ka ligament ma ke kuli a me nā kuʻekuʻe wāwae i ʻike pinepine ʻia i nā mea pāʻani, hiki i ka BPC-157 ke hoʻolalelale i ka hoʻoponopono ʻana i nā ʻiʻo i hōʻino ʻia, hoʻopōkole i ka manawa hoʻoponopono, a hoʻonui i ka wikiwiki o ka hoʻihoʻi ʻana o ka hana haʻuki.
Ka hopena
Ma ke ʻano he peptide bioactive me nā hana hoʻoponopono he nui, hōʻike ʻo BPC-157 i kekahi pono i ka hana o ka hoʻoponopono ʻana i ka ʻeha a me ka ʻeha.
Nā kumu
[1] Lee E, Padgett B J. Intra-Articular Injection of BPC 157 no nā ʻano he nui o ka ʻeha kuli.[J]. Nā Lapaʻau ʻē aʻe i ke olakino a me ka lāʻau lapaʻau, 2021,27 4:8-13.DOI:https://api.semanticscholar.org/CorpusID:236516759.
[2] Sikiric P, Drmic D, Sever M, et al. Ho'ōla Fistula. Kūpaʻa Gastric Pentadecapeptide BPC 157 Therapy[J]. Hoʻolālā Lapaʻau o kēia manawa, 2020,26(25):2991-3000.DOI:10.2174/ 13816128266 66200424180139.
[3] Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, a me Selye's Stress Coping Pane: Holomua, Loaʻa, a me ka wā e hiki mai ana[J]. Puu a me ka Aʻa, 2020,14(2):153-167.DOI:10.5009/gnl18490.
[4] Huang T, Zhang K, Sun L, a me al. Hoʻonui ka hui pale kino-157 i ka ho'ōla ʻana i ka ʻeha alkali-burn in vivo a hoʻoikaika i ka hoʻonui, neʻe ʻana, a me ka angiogenesis in vitro [J]. Drug Des Devel Ther, 2015,9:2485-2499.DOI:10.2147/DDDT.S82030.
[5] Kokic N, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC-157 a me ka ʻiole temporomandibular joint osteoarthrosis [M]. 2001.https://www.researchgate.net/publication/266736896_Pentadecapeptide_BPC-157_and_rat_temporomandibular_joint_osteoarthrosis.
[6] Sikirić P, Seiwerth S, Grabarević Z, et al. ʻO ka hopena maikaʻi a me ka prophylactic o pentadecapeptide BPC 157 ma ka maʻi pancreatitis a me nā maʻi gastroduodenal concomitant i nā ʻiole [J]. ʻO nā maʻi a me ka ʻepekema ʻana, 1996,41(7):1518-1526.DOI:10.1007/BF02088582.
Loaʻa ka huahana no ka noiʻi wale nō:
